October 23, 2014 1:13 PM ET


Company Overview of Advanced Accelerator Applications SA

Company Overview

Advanced Accelerator Applications SA is engaged in the research, development, production, and distribution of molecular imaging and molecular therapy products. It offers positron emission tomography (PET) and single photon emission tomography radiopharmaceuticals for molecular diagnostics and therapy. The company provides Fluoro Deoxy Glucose that is used to assess glucose metabolism in the brain, including Alzheimer’s disease, dementia, epilepsy, brain trauma, Huntington disease, cerebrovascular disorders, brain tumors, schizophrenia, and mood disorders; cancer, including lung, colorectal, esophageal, head and neck, breast and thyroid carcinoma, melanoma, and lymphoma; cardiovascular diseas...

20 Rue Diesel

Saint Genis Pouilly,  01630


Founded in 2002


33 4 50 99 30 70


33 4 50 99 30 71

Key Executives for Advanced Accelerator Applications SA

Age: 48
Group Chief Financial Officer and Director
Age: 51
Chief Operating Officer and Director
Age: 56
Group Head of R&D
Age: 56
Head of Clinical Development
Age: 59
Compensation as of Fiscal Year 2014.

Advanced Accelerator Applications SA Key Developments

Advanced Accelerator Applications SA Announces Earnings Results for the Full Year Ended December 31, 2013

Advanced Accelerator Applications SA announced earnings results for the full year ended December 31, 2013. For the period, the company reported net loss for the year from continuing operations of EUR 9,861,000 compared with EUR 16,912,000 for the same period a year ago. EBITDA was EUR 10,638,000 compared with EUR 6,577,000 for the same period a year ago. Sales for the year increased by 31.77% to EUR 53.8 million compared with EUR 40.8 million for the same period a year ago.

Advanced Accelerator Applications SA Appoints Kapil Dhingra as Independent Non-Executive Director

Advanced Accelerator Applications S.A. announced that Dr. Kapil Dhingra has joined the company Board of Directors as an Independent Non-Executive Director. Dr. Dhingra has over 25 year's experience in oncology clinical research and drug development, including nine years at Roche Pharmaceuticals, where he played a key role in the expansion of Roche Oncology. From 1999 to 2008 he served in positions of increasing responsibility at Roche, including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to his time at Roche, Dr. Dhingra worked in the oncology clinical development group at Eli Lilly and Company. He has also previously served as a Clinical Instructor, Assistant Professor of Medicine at the University of Texas M.D. Anderson Cancer Center. Dr. Dhingra holds an M.B.,B.S. (equivalent to a U.S. M.D.) degree from the All India Institute of Medical Sciences. He is Board-certified in Internal Medicine and Medical Oncology.

Advanced Accelerator Applications SA Presents at UBS Global Healthcare Conference, May-19-2014 04:00 PM

Advanced Accelerator Applications SA Presents at UBS Global Healthcare Conference, May-19-2014 04:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Stefano Buono, Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Bioluz S.A. Europe
Mellitech SAS Europe
Institut De Recherche Biologique S.A. Europe
Janssen-cilag International Nv Europe
Fovea Pharmaceuticals SA Europe

Recent Private Companies Transactions

March 4, 2014
Imaging Equipment Ltd
Private Placement
February 17, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Advanced Accelerator Applications SA, please visit www.adacap.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.